China · Delayed Price · Currency is CNY Acrobiosystems Statistics
Total Valuation
Acrobiosystems has a market cap or net worth of CNY 13.16 billion. The enterprise value is 12.17 billion.
| Market Cap | 13.16B |
| Enterprise Value | 12.17B |
Important Dates
The last earnings date was Saturday, August 29, 2026.
| Earnings Date | Aug 29, 2026 |
| Ex-Dividend Date | Jun 11, 2026 |
Share Statistics
Acrobiosystems has 167.18 million shares outstanding. The number of shares has decreased by -3.24% in one year.
| Current Share Class | 167.18M |
| Shares Outstanding | 167.18M |
| Shares Change (YoY) | -3.24% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 35.22% |
| Owned by Institutions (%) | 11.88% |
| Float | 91.11M |
Valuation Ratios
The trailing PE ratio is 72.01 and the forward PE ratio is 43.48.
| PE Ratio | 72.01 |
| Forward PE | 43.48 |
| PS Ratio | 13.84 |
| PB Ratio | 4.95 |
| P/TBV Ratio | 5.01 |
| P/FCF Ratio | 100.56 |
| P/OCF Ratio | 35.04 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.45, with an EV/FCF ratio of 93.04.
| EV / Earnings | 67.58 |
| EV / Sales | 12.81 |
| EV / EBITDA | 48.45 |
| EV / EBIT | 64.46 |
| EV / FCF | 93.04 |
Financial Position
The company has a current ratio of 8.42, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.42 |
| Quick Ratio | 6.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.68 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 6.83% and return on invested capital (ROIC) is 11.72%.
| Return on Equity (ROE) | 6.83% |
| Return on Assets (ROA) | 4.01% |
| Return on Invested Capital (ROIC) | 11.72% |
| Return on Capital Employed (ROCE) | 6.70% |
| Weighted Average Cost of Capital (WACC) | 8.15% |
| Revenue Per Employee | 1.03M |
| Profits Per Employee | 194,514 |
| Employee Count | 926 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.49 |
Taxes
In the past 12 months, Acrobiosystems has paid 4.51 million in taxes.
| Income Tax | 4.51M |
| Effective Tax Rate | 2.44% |
Stock Price Statistics
The stock price has increased by +34.21% in the last 52 weeks. The beta is 0.72, so Acrobiosystems's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +34.21% |
| 50-Day Moving Average | 69.03 |
| 200-Day Moving Average | 53.90 |
| Relative Strength Index (RSI) | 48.64 |
| Average Volume (20 Days) | 16,096,958 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Acrobiosystems had revenue of CNY 950.35 million and earned 180.12 million in profits. Earnings per share was 1.09.
| Revenue | 950.35M |
| Gross Profit | 823.92M |
| Operating Income | 188.84M |
| Pretax Income | 184.32M |
| Net Income | 180.12M |
| EBITDA | 236.85M |
| EBIT | 188.84M |
| Earnings Per Share (EPS) | 1.09 |
Balance Sheet
The company has 1.07 billion in cash and 89.00 million in debt, with a net cash position of 983.66 million or 5.88 per share.
| Cash & Cash Equivalents | 1.07B |
| Total Debt | 89.00M |
| Net Cash | 983.66M |
| Net Cash Per Share | 5.88 |
| Equity (Book Value) | 2.66B |
| Book Value Per Share | 15.90 |
| Working Capital | 1.39B |
Cash Flow
In the last 12 months, operating cash flow was 375.45 million and capital expenditures -244.62 million, giving a free cash flow of 130.84 million.
| Operating Cash Flow | 375.45M |
| Capital Expenditures | -244.62M |
| Depreciation & Amortization | 48.01M |
| Net Borrowing | 12.78M |
| Free Cash Flow | 130.84M |
| FCF Per Share | 0.78 |
Margins
Gross margin is 86.70%, with operating and profit margins of 19.87% and 18.95%.
| Gross Margin | 86.70% |
| Operating Margin | 19.87% |
| Pretax Margin | 19.39% |
| Profit Margin | 18.95% |
| EBITDA Margin | 24.92% |
| EBIT Margin | 19.87% |
| FCF Margin | 13.77% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.70%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.70% |
| Dividend Growth (YoY) | -2.33% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 82.50% |
| Buyback Yield | 3.24% |
| Shareholder Yield | 3.94% |
| Earnings Yield | 1.37% |
| FCF Yield | 0.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Acrobiosystems is 81.51, which is 3.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 81.51 |
| Price Target Difference | 3.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 22.98% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on July 11, 2025. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |